DelistingJul 2, 2026, 04:14 PM
Barinthus Biotherapeutics Gets Nasdaq Delisting Extension to Dec 28
AI Summary
Barinthus Biotherapeutics received an extension from Nasdaq until December 28, 2026, to regain compliance with the minimum $1.00 bid price requirement, following its transfer to the Nasdaq Capital Market. The company is actively monitoring its stock price and considering options, including a reverse stock split, to avoid delisting. Additionally, the company held its 2026 Annual General Meeting where all matters were approved, including the re-election of directors and the re-appointment of auditors, with no dividend recommended for fiscal year 2025.
Key Highlights
- Received Nasdaq delisting extension until December 28, 2026.
- Transferred from Nasdaq Global Market to Nasdaq Capital Market.
- Company considering options including a reverse stock split to regain compliance.
- 2026 Annual General Meeting held on July 2, 2026.
- All matters submitted to stockholders at AGM were approved.
- Karen T. Dawes and Anne M. Phillips re-elected as directors.
- PricewaterhouseCoopers LLP re-appointed as UK statutory auditors.
- No dividend recommended for fiscal year ended December 31, 2025.
Price Impact
More from BRNS